The Aducanumab Aftermath: The Patient
from Tradeoffs
Desperate to slow her cognitive decline, one patient shares her hopes and concerns about the first new Alzheimer’s drug in nearly 20 years. This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending. Guest: Arthena Caston, Alzheimer’s patient and advocate Explore the full series and additional resources: https://tradeoffs.org/aducanumab Read a transcript of this episode: https://tradeoffs.org/2021/06/23/the-aducanumab-aftermath-the-patient/ Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter Support this type of journalism today, with a gift: https://tradeoffs.org/donate Follow us on Twitter: https://twitter.com/tradeoffspod
Embed this episode
No transcript yet.